Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-06-30 DOI:10.1038/s41571-025-01055-5

Josep M. Llovet

引用次数: 0

Abstract

Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.

查看原文本刊更多论文

新型免疫治疗组合在晚期肝癌治疗中的作用

免疫检查点抑制剂彻底改变了肝细胞癌的治疗。目前，抗pd -(L)-1抗体联合贝伐单抗或抗ctla4抗体是晚期肿瘤的标准治疗方案。现在，两项III期研究（CheckMate 9DW和APOLLO）在一线环境中报告了积极的生存结果，尽管对临床实践有不同的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.